Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 280 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Testosterone Therapy Clear all

Conditions: Healthy Participants
Interventions: Testosterone, Deodorant Spray, Deodorant and Antiperspirant Combination Spray, Deodorant and Antiperspirant Combination Stick; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Daytona Beach, Florida • Evansville, Indiana

Conditions: Prostate Cancer
Interventions: Exisulind, luteinizing hormone-releasing hormone (LHRH) agonist, Antiandrogen; Drug
Lead sponsor: University of Washington; Other
Eligibility: 21 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Adenocarcinoma
Interventions: Osanetant; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Aqueous Tear Deficiency, Meibomian Gland Dysfunction of Bilateral Eyes (Disorder)
Interventions: Testosterone gel 4.5%, Vehicle gel; Drug
Lead sponsor: Southern California College of Optometry at Marshall B. Ketchum University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Fullerton, California

Conditions: Prostate Cancer
Interventions: Testosterone cypionate, Testosterone Enanthate, Abiraterone acetate, Enzalutamide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Prostate Cancer
Interventions: AAA817, ARPI, Standard of Care; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 940 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 42
States / cities: Homewood, Alabama • Tucson, Arizona • Orange, California + 37 more

Conditions: Type 2 Diabetes Mellitus, Hypogonadism
Interventions: Testosterone gel 1.62%, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 35 Years to 70 Years · Male only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypogonadism
Interventions: TSX-002; Drug
Lead sponsor: TesoRx Pharma, LLC; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
Interventions: Testosterone cypionate, Nivolumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Boston, Massachusetts

Conditions: Endocrine Dysfunction, Trauma, Brain Injury
Interventions: Androgel (Testosterone Gel), Placebo gel; Drug · Other
Lead sponsor: Craig Hospital; Other
Eligibility: 16 Years to 65 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Premature Ovarian Failure
Interventions: Dehydroepiandrosterone, Placebo; Dietary Supplement
Lead sponsor: David H. Barad; Other
Eligibility: 21 Years to 39 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypoactive Sexual Desire Disorder (HSDD)
Interventions: Testosterone Transdermal System, Placebo patch; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Elderly, Prostate Cancer
Interventions: LHRH Agonist Therapy Discontinuation; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 70 Years and older · Male only
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Sleep Apnea, Elderly Adults
Interventions: Hyperoxia/oxygen, Acetazolamide, Finasteride; Other · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years to 89 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Menopause
Interventions: esterified estrogens 0.625 mg and methyltestosterone 1.25 mg; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 77
States / cities: Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 74 more

Conditions: Meibomian Gland Dysfunction
Interventions: testosterone ophthalmic solution, vehicle of testosterone ophthalmic solution; Drug
Lead sponsor: ORA, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: HIV/AIDS, Gender, Behavior and Behavior Mechanisms
Interventions: TDF/FTC; Drug
Lead sponsor: Hektoen Institute for Medical Research; Other
Eligibility: 15 Years to 24 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hypoactive Sexual Desire Disorder
Interventions: testosterone gel, placebo gel; Drug
Lead sponsor: BioSante Pharmaceuticals; Industry
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 60
States / cities: Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 56 more

Conditions: Prostate Cancer
Interventions: Prednisone, Apalutamide, Abiraterone Acetate, LHRH Agonist or Antagonist; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: Boston, Massachusetts • Milford, Massachusetts • South Weymouth, Massachusetts

Conditions: Multiple Sclerosis
Interventions: AndroGel 1 % Topical Gel, Placebos; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 60 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Los Angeles, California • St Louis, Missouri

Conditions: Prostatic Neoplasms
Interventions: Zolpidem, ECG; Drug · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Physical Frailty, Hip Fracture, Elective Hip Replacement, Hypogonadism
Interventions: Transdermal Testosterone gel (1%), Supervised exercise training; Drug · Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 65 Years and older · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hypogonadism
Interventions: Testerone Transdermal System; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Miramar, Florida • Omaha, Nebraska • San Antonio, Texas

Conditions: Pain, Hypogonadism
Interventions: AndroGel, Placebo; Drug · Other
Lead sponsor: Boston University; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Study of Effect of Deodorant and Axillary Hair on Testosterone Absorption in Healthy Participants

Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate

Eyelid Androgen Treatment in Dry Eye

RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism

Oral Testosterone for the Treatment of Hypogonadism in Males

COMbination of Bipolar Androgen Therapy and Nivolumab

Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy

Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)

Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido

Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

Sleep Apnea in Elderly

Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women

Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction

Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study

Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

Testosterone for Fatigue in Men With MS

The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

Exercise and Testosterone Therapy in Elderly Men With Physical Frailty

Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men

Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception